19 Result(s)
within
Victor L. Villemagne
Neurology
-
Article
The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias
Molecular neuroimaging based on annihilation radiation tomographic (ART) techniques such as positron emission tomography (PET), in conjunction with related biomarkers in plasma and cerebrospinal fluid (CSF), a...
-
Protocol
Emission Imaging in Dementia
Dementia is typically associated with progressive impairments in memory and cognition that are beyond what is expected during the normal aging process; these impairments can also be accompanied by behavioral a...
-
Article
Open Access18F-florbetaben Aβ imaging in mild cognitive impairment
18F-florbetaben and positron emission tomography were used to examine the relationships between β-amyloid (Aβ) deposition, cognition, hippocampal volume, and white matter hyperintensities in mild cognitive impai....
-
Article
Open AccessAssessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies
The introduction of tau imaging agents such as 18F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminary 18F-THK523-PET studies hav...
-
Article
Open AccessImago Mundi, Imago AD, Imago ADNI
Since the launch in 2003 of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) in the USA, ever growing, similarly oriented consortia have been organized and assembled around the world. The various accompl...
-
Article
The landscape of ageing—insights from AD imaging markers
The knowledge of imaging and fluid biomarkers gained from longitudinal observational studies of Alzheimer disease has recently been translated to a cross-sectional study of randomly selected, cognitively unimp...
-
Article
Suspected non-Alzheimer disease pathophysiology — concept and controversy
Suspected non-Alzheimer disease pathophysiology (SNAP) is a biomarker-based concept that applies to individuals with normal levels of amyloid-β biomarkers in the brain, but in whom biomarkers of neurodegenerat...
-
Article
Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia
In a group of older adults with very mild dementia, we aimed to characterize the nature and magnitude of cognitive decline as measured by the Cogstate Brief Battery, in relation to Aβ levels and hippocampal vo...
-
Article
A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer’s Disease
This commentary outlines a conceptual model for subjective cognitive decline (SCD) in relation to Alzheimer’s disease (AD) biomarkers in the preclinical stages of disease and a framework for effectively utiliz...
-
Article
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
The clinical phenotypes of patients with proteinopathies do not always enable identification of the underlying cause of the disorder, especially in early disea...
-
Article
Author Correction: Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
In Figure 1 of this article as originally published, the chemical structure at bottom right was incorrectly labelled 18F-PM-PBB3. The text label has been corrected to 18F-PBB3 in the PDF and HTML versions of the ...
-
Article
Open AccessComparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
The Centiloid scale was developed to standardise the results of beta-amyloid (Aβ) PET. We aimed to determine the Centiloid unit (CL) thresholds for CERAD sparse and moderate-density neuritic plaques, Alzheimer...
-
Article
Open AccessElecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous researc...
-
Chapter
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions
In vivo imaging of β-amyloid (Αβ) has transformed the assessment of Αβ pathology and its changes over time, extending our insight into Aβ deposition in the brain by providing highly accurate, reliable, and rep...
-
Article
Open AccessEarly detection of amyloid load using 18F-florbetaben PET
A low amount and extent of Aβ deposition at early stages of Alzheimer’s disease (AD) may limit the use of previously developed pathology-proven composite SUVR cutoffs. This study aims to characterize the popul...
-
Article
Open AccessCore Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods
CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profil...
-
Article
Open AccessMesial temporal tau in amyloid-β-negative cognitively normal older persons
Tau deposition in the mesial temporal lobe (MTL) in the absence of amyloid-β (Aβ−) occurs with aging. The tau PET tracer 18F-MK6240 has low non-specific background binding so is well suited to exploration of earl...
-
Chapter
Traits and Trammels of Tau Tracer Imaging
Tau aggregates are the neuropathological hallmark of neurodegenerative conditions known as tauopathies. The introduction of in vivo imaging of tau pathology, added to Aβ-amyloid imaging, has revolutionized the...
-
Article
Open AccessAlzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting
Alzheimer’s disease (AD), the most common form of dementia, remains challenging to understand and treat despite decades of research and clinical investigation. This might be partly due to a lack of widely avai...
